img

Global Oligonucleotide Drugs (ONs) Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Oligonucleotide Drugs (ONs) Market Insights, Forecast to 2034

Nucleic acid medicines utilize nucleic acid, which refer to substances such as DNA and RNA that control genetic information, as drugs. These allow targeting of molecules such as mRNA and miRNA that cannot be targeted with traditional low molecular weight drugs and antibody medicines, and there is a great expectation for these drugs as next generation pharmaceuticals. Active research is being conducted globally as it is expected to lead to the creation of drugs which were previously intractable.
Global Oligonucleotide Drugs (ONs) market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Oligonucleotide Drugs (ONs) industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Oligonucleotide drugs (ONs) represent an emerging class of biopharmaceutical products that have witnessed remarkable development in recent years. The market size has been progressively expanding, with diverse applications spanning gene therapy, oncology, and orphan diseases. ONs have garnered attention for their highly precise mechanisms of action and relatively low risk of adverse effects, leading to the approval of several drugs for clinical use. With continuous advancements in research and technology, the future of oligonucleotide drugs holds promise in further extending their applications to areas like tumor immunotherapy and treatment of genetic disorders, offering patients more precise and effective therapeutic options.
Report Covers
This report presents an overview of global Oligonucleotide Drugs (ONs) market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Oligonucleotide Drugs (ONs) market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Novartis
Ionis
Nippon Shinyaku
Alnylam
Sarepta Therapeutics
MiNA Therapeutics
BioNTech
Moderna
Segment by Type
ASO
siRNA
Other

Segment by Application


Cardiovascular Diseases
Hepatitis B
Hypertension
Other

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Oligonucleotide Drugs (ONs) plant distribution, commercial date of Oligonucleotide Drugs (ONs), product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Oligonucleotide Drugs (ONs) introduction, etc. Oligonucleotide Drugs (ONs) Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Oligonucleotide Drugs (ONs)
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Oligonucleotide Drugs (ONs) Product Introduction
1.2 Market by Type
1.2.1 Global Oligonucleotide Drugs (ONs) Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 ASO
1.2.3 siRNA
1.2.4 Other
1.3 Market by Application
1.3.1 Global Oligonucleotide Drugs (ONs) Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Cardiovascular Diseases
1.3.3 Hepatitis B
1.3.4 Hypertension
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oligonucleotide Drugs (ONs) Sales Estimates and Forecasts 2018-2029
2.2 Global Oligonucleotide Drugs (ONs) Revenue by Region
2.2.1 Global Oligonucleotide Drugs (ONs) Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Oligonucleotide Drugs (ONs) Revenue by Region (2018-2024)
2.2.3 Global Oligonucleotide Drugs (ONs) Revenue by Region (2024-2029)
2.2.4 Global Oligonucleotide Drugs (ONs) Revenue Market Share by Region (2018-2029)
2.3 Global Oligonucleotide Drugs (ONs) Sales Estimates and Forecasts 2018-2029
2.4 Global Oligonucleotide Drugs (ONs) Sales by Region
2.4.1 Global Oligonucleotide Drugs (ONs) Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Oligonucleotide Drugs (ONs) Sales by Region (2018-2024)
2.4.3 Global Oligonucleotide Drugs (ONs) Sales by Region (2024-2029)
2.4.4 Global Oligonucleotide Drugs (ONs) Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Oligonucleotide Drugs (ONs) Sales by Manufacturers
3.1.1 Global Oligonucleotide Drugs (ONs) Sales by Manufacturers (2018-2024)
3.1.2 Global Oligonucleotide Drugs (ONs) Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Oligonucleotide Drugs (ONs) in 2022
3.2 Global Oligonucleotide Drugs (ONs) Revenue by Manufacturers
3.2.1 Global Oligonucleotide Drugs (ONs) Revenue by Manufacturers (2018-2024)
3.2.2 Global Oligonucleotide Drugs (ONs) Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Oligonucleotide Drugs (ONs) Revenue in 2022
3.3 Global Key Players of Oligonucleotide Drugs (ONs), Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Oligonucleotide Drugs (ONs) Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Oligonucleotide Drugs (ONs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Oligonucleotide Drugs (ONs), Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Oligonucleotide Drugs (ONs), Product Offered and Application
3.8 Global Key Manufacturers of Oligonucleotide Drugs (ONs), Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Oligonucleotide Drugs (ONs) Sales by Type
4.1.1 Global Oligonucleotide Drugs (ONs) Historical Sales by Type (2018-2024)
4.1.2 Global Oligonucleotide Drugs (ONs) Forecasted Sales by Type (2024-2029)
4.1.3 Global Oligonucleotide Drugs (ONs) Sales Market Share by Type (2018-2029)
4.2 Global Oligonucleotide Drugs (ONs) Revenue by Type
4.2.1 Global Oligonucleotide Drugs (ONs) Historical Revenue by Type (2018-2024)
4.2.2 Global Oligonucleotide Drugs (ONs) Forecasted Revenue by Type (2024-2029)
4.2.3 Global Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2018-2029)
4.3 Global Oligonucleotide Drugs (ONs) Price by Type
4.3.1 Global Oligonucleotide Drugs (ONs) Price by Type (2018-2024)
4.3.2 Global Oligonucleotide Drugs (ONs) Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Oligonucleotide Drugs (ONs) Sales by Application
5.1.1 Global Oligonucleotide Drugs (ONs) Historical Sales by Application (2018-2024)
5.1.2 Global Oligonucleotide Drugs (ONs) Forecasted Sales by Application (2024-2029)
5.1.3 Global Oligonucleotide Drugs (ONs) Sales Market Share by Application (2018-2029)
5.2 Global Oligonucleotide Drugs (ONs) Revenue by Application
5.2.1 Global Oligonucleotide Drugs (ONs) Historical Revenue by Application (2018-2024)
5.2.2 Global Oligonucleotide Drugs (ONs) Forecasted Revenue by Application (2024-2029)
5.2.3 Global Oligonucleotide Drugs (ONs) Revenue Market Share by Application (2018-2029)
5.3 Global Oligonucleotide Drugs (ONs) Price by Application
5.3.1 Global Oligonucleotide Drugs (ONs) Price by Application (2018-2024)
5.3.2 Global Oligonucleotide Drugs (ONs) Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Oligonucleotide Drugs (ONs) Market Size by Type
6.1.1 US & Canada Oligonucleotide Drugs (ONs) Sales by Type (2018-2029)
6.1.2 US & Canada Oligonucleotide Drugs (ONs) Revenue by Type (2018-2029)
6.2 US & Canada Oligonucleotide Drugs (ONs) Market Size by Application
6.2.1 US & Canada Oligonucleotide Drugs (ONs) Sales by Application (2018-2029)
6.2.2 US & Canada Oligonucleotide Drugs (ONs) Revenue by Application (2018-2029)
6.3 US & Canada Oligonucleotide Drugs (ONs) Market Size by Country
6.3.1 US & Canada Oligonucleotide Drugs (ONs) Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Oligonucleotide Drugs (ONs) Sales by Country (2018-2029)
6.3.3 US & Canada Oligonucleotide Drugs (ONs) Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Oligonucleotide Drugs (ONs) Market Size by Type
7.1.1 Europe Oligonucleotide Drugs (ONs) Sales by Type (2018-2029)
7.1.2 Europe Oligonucleotide Drugs (ONs) Revenue by Type (2018-2029)
7.2 Europe Oligonucleotide Drugs (ONs) Market Size by Application
7.2.1 Europe Oligonucleotide Drugs (ONs) Sales by Application (2018-2029)
7.2.2 Europe Oligonucleotide Drugs (ONs) Revenue by Application (2018-2029)
7.3 Europe Oligonucleotide Drugs (ONs) Market Size by Country
7.3.1 Europe Oligonucleotide Drugs (ONs) Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Oligonucleotide Drugs (ONs) Sales by Country (2018-2029)
7.3.3 Europe Oligonucleotide Drugs (ONs) Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Oligonucleotide Drugs (ONs) Market Size
8.1.1 China Oligonucleotide Drugs (ONs) Sales (2018-2029)
8.1.2 China Oligonucleotide Drugs (ONs) Revenue (2018-2029)
8.2 China Oligonucleotide Drugs (ONs) Market Size by Application
8.2.1 China Oligonucleotide Drugs (ONs) Sales by Application (2018-2029)
8.2.2 China Oligonucleotide Drugs (ONs) Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Oligonucleotide Drugs (ONs) Market Size by Type
9.1.1 Asia Oligonucleotide Drugs (ONs) Sales by Type (2018-2029)
9.1.2 Asia Oligonucleotide Drugs (ONs) Revenue by Type (2018-2029)
9.2 Asia Oligonucleotide Drugs (ONs) Market Size by Application
9.2.1 Asia Oligonucleotide Drugs (ONs) Sales by Application (2018-2029)
9.2.2 Asia Oligonucleotide Drugs (ONs) Revenue by Application (2018-2029)
9.3 Asia Oligonucleotide Drugs (ONs) Sales by Region
9.3.1 Asia Oligonucleotide Drugs (ONs) Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Oligonucleotide Drugs (ONs) Revenue by Region (2018-2029)
9.3.3 Asia Oligonucleotide Drugs (ONs) Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Market Size by Type
10.1.1 Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Market Size by Application
10.2.1 Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales by Country
10.3.1 Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Overview
11.1.3 Novartis Oligonucleotide Drugs (ONs) Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Novartis Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novartis Recent Developments
11.2 Ionis
11.2.1 Ionis Company Information
11.2.2 Ionis Overview
11.2.3 Ionis Oligonucleotide Drugs (ONs) Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Ionis Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Ionis Recent Developments
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Company Information
11.3.2 Nippon Shinyaku Overview
11.3.3 Nippon Shinyaku Oligonucleotide Drugs (ONs) Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Nippon Shinyaku Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Nippon Shinyaku Recent Developments
11.4 Alnylam
11.4.1 Alnylam Company Information
11.4.2 Alnylam Overview
11.4.3 Alnylam Oligonucleotide Drugs (ONs) Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Alnylam Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Alnylam Recent Developments
11.5 Sarepta Therapeutics
11.5.1 Sarepta Therapeutics Company Information
11.5.2 Sarepta Therapeutics Overview
11.5.3 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Sarepta Therapeutics Recent Developments
11.6 MiNA Therapeutics
11.6.1 MiNA Therapeutics Company Information
11.6.2 MiNA Therapeutics Overview
11.6.3 MiNA Therapeutics Oligonucleotide Drugs (ONs) Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 MiNA Therapeutics Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 MiNA Therapeutics Recent Developments
11.7 BioNTech
11.7.1 BioNTech Company Information
11.7.2 BioNTech Overview
11.7.3 BioNTech Oligonucleotide Drugs (ONs) Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 BioNTech Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 BioNTech Recent Developments
11.8 Moderna
11.8.1 Moderna Company Information
11.8.2 Moderna Overview
11.8.3 Moderna Oligonucleotide Drugs (ONs) Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Moderna Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Moderna Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Oligonucleotide Drugs (ONs) Industry Chain Analysis
12.2 Oligonucleotide Drugs (ONs) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Oligonucleotide Drugs (ONs) Production Mode & Process
12.4 Oligonucleotide Drugs (ONs) Sales and Marketing
12.4.1 Oligonucleotide Drugs (ONs) Sales Channels
12.4.2 Oligonucleotide Drugs (ONs) Distributors
12.5 Oligonucleotide Drugs (ONs) Customers
13 Market Dynamics
13.1 Oligonucleotide Drugs (ONs) Industry Trends
13.2 Oligonucleotide Drugs (ONs) Market Drivers
13.3 Oligonucleotide Drugs (ONs) Market Challenges
13.4 Oligonucleotide Drugs (ONs) Market Restraints
14 Key Findings in The Global Oligonucleotide Drugs (ONs) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Oligonucleotide Drugs (ONs) Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of ASO
Table 3. Major Manufacturers of siRNA
Table 4. Major Manufacturers of Other
Table 5. Global Oligonucleotide Drugs (ONs) Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Oligonucleotide Drugs (ONs) Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Oligonucleotide Drugs (ONs) Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Oligonucleotide Drugs (ONs) Revenue by Region (2024-2029) & (US$ Million)
Table 9. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Region (2018-2024)
Table 10. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Region (2024-2029)
Table 11. Global Oligonucleotide Drugs (ONs) Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Oligonucleotide Drugs (ONs) Sales by Region (2018-2024) & (K Units)
Table 13. Global Oligonucleotide Drugs (ONs) Sales by Region (2024-2029) & (K Units)
Table 14. Global Oligonucleotide Drugs (ONs) Sales Market Share by Region (2018-2024)
Table 15. Global Oligonucleotide Drugs (ONs) Sales Market Share by Region (2024-2029)
Table 16. Global Oligonucleotide Drugs (ONs) Sales by Manufacturers (2018-2024) & (K Units)
Table 17. Global Oligonucleotide Drugs (ONs) Sales Share by Manufacturers (2018-2024)
Table 18. Global Oligonucleotide Drugs (ONs) Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Oligonucleotide Drugs (ONs) Revenue Share by Manufacturers (2018-2024)
Table 20. Global Key Players of Oligonucleotide Drugs (ONs), Industry Ranking, 2021 VS 2022 VS 2024
Table 21. Oligonucleotide Drugs (ONs) Price by Manufacturers 2018-2024 (US$/Unit)
Table 22. Global Oligonucleotide Drugs (ONs) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Oligonucleotide Drugs (ONs) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Drugs (ONs) as of 2022)
Table 24. Global Key Manufacturers of Oligonucleotide Drugs (ONs), Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Oligonucleotide Drugs (ONs), Product Offered and Application
Table 26. Global Key Manufacturers of Oligonucleotide Drugs (ONs), Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Oligonucleotide Drugs (ONs) Sales by Type (2018-2024) & (K Units)
Table 29. Global Oligonucleotide Drugs (ONs) Sales by Type (2024-2029) & (K Units)
Table 30. Global Oligonucleotide Drugs (ONs) Sales Share by Type (2018-2024)
Table 31. Global Oligonucleotide Drugs (ONs) Sales Share by Type (2024-2029)
Table 32. Global Oligonucleotide Drugs (ONs) Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Oligonucleotide Drugs (ONs) Revenue by Type (2024-2029) & (US$ Million)
Table 34. Global Oligonucleotide Drugs (ONs) Revenue Share by Type (2018-2024)
Table 35. Global Oligonucleotide Drugs (ONs) Revenue Share by Type (2024-2029)
Table 36. Oligonucleotide Drugs (ONs) Price by Type (2018-2024) & (US$/Unit)
Table 37. Global Oligonucleotide Drugs (ONs) Price Forecast by Type (2024-2029) & (US$/Unit)
Table 38. Global Oligonucleotide Drugs (ONs) Sales by Application (2018-2024) & (K Units)
Table 39. Global Oligonucleotide Drugs (ONs) Sales by Application (2024-2029) & (K Units)
Table 40. Global Oligonucleotide Drugs (ONs) Sales Share by Application (2018-2024)
Table 41. Global Oligonucleotide Drugs (ONs) Sales Share by Application (2024-2029)
Table 42. Global Oligonucleotide Drugs (ONs) Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Oligonucleotide Drugs (ONs) Revenue by Application (2024-2029) & (US$ Million)
Table 44. Global Oligonucleotide Drugs (ONs) Revenue Share by Application (2018-2024)
Table 45. Global Oligonucleotide Drugs (ONs) Revenue Share by Application (2024-2029)
Table 46. Oligonucleotide Drugs (ONs) Price by Application (2018-2024) & (US$/Unit)
Table 47. Global Oligonucleotide Drugs (ONs) Price Forecast by Application (2024-2029) & (US$/Unit)
Table 48. US & Canada Oligonucleotide Drugs (ONs) Sales by Type (2018-2024) & (K Units)
Table 49. US & Canada Oligonucleotide Drugs (ONs) Sales by Type (2024-2029) & (K Units)
Table 50. US & Canada Oligonucleotide Drugs (ONs) Revenue by Type (2018-2024) & (US$ Million)
Table 51. US & Canada Oligonucleotide Drugs (ONs) Revenue by Type (2024-2029) & (US$ Million)
Table 52. US & Canada Oligonucleotide Drugs (ONs) Sales by Application (2018-2024) & (K Units)
Table 53. US & Canada Oligonucleotide Drugs (ONs) Sales by Application (2024-2029) & (K Units)
Table 54. US & Canada Oligonucleotide Drugs (ONs) Revenue by Application (2018-2024) & (US$ Million)
Table 55. US & Canada Oligonucleotide Drugs (ONs) Revenue by Application (2024-2029) & (US$ Million)
Table 56. US & Canada Oligonucleotide Drugs (ONs) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 57. US & Canada Oligonucleotide Drugs (ONs) Revenue by Country (2018-2024) & (US$ Million)
Table 58. US & Canada Oligonucleotide Drugs (ONs) Revenue by Country (2024-2029) & (US$ Million)
Table 59. US & Canada Oligonucleotide Drugs (ONs) Sales by Country (2018-2024) & (K Units)
Table 60. US & Canada Oligonucleotide Drugs (ONs) Sales by Country (2024-2029) & (K Units)
Table 61. Europe Oligonucleotide Drugs (ONs) Sales by Type (2018-2024) & (K Units)
Table 62. Europe Oligonucleotide Drugs (ONs) Sales by Type (2024-2029) & (K Units)
Table 63. Europe Oligonucleotide Drugs (ONs) Revenue by Type (2018-2024) & (US$ Million)
Table 64. Europe Oligonucleotide Drugs (ONs) Revenue by Type (2024-2029) & (US$ Million)
Table 65. Europe Oligonucleotide Drugs (ONs) Sales by Application (2018-2024) & (K Units)
Table 66. Europe Oligonucleotide Drugs (ONs) Sales by Application (2024-2029) & (K Units)
Table 67. Europe Oligonucleotide Drugs (ONs) Revenue by Application (2018-2024) & (US$ Million)
Table 68. Europe Oligonucleotide Drugs (ONs) Revenue by Application (2024-2029) & (US$ Million)
Table 69. Europe Oligonucleotide Drugs (ONs) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 70. Europe Oligonucleotide Drugs (ONs) Revenue by Country (2018-2024) & (US$ Million)
Table 71. Europe Oligonucleotide Drugs (ONs) Revenue by Country (2024-2029) & (US$ Million)
Table 72. Europe Oligonucleotide Drugs (ONs) Sales by Country (2018-2024) & (K Units)
Table 73. Europe Oligonucleotide Drugs (ONs) Sales by Country (2024-2029) & (K Units)
Table 74. China Oligonucleotide Drugs (ONs) Sales by Type (2018-2024) & (K Units)
Table 75. China Oligonucleotide Drugs (ONs) Sales by Type (2024-2029) & (K Units)
Table 76. China Oligonucleotide Drugs (ONs) Revenue by Type (2018-2024) & (US$ Million)
Table 77. China Oligonucleotide Drugs (ONs) Revenue by Type (2024-2029) & (US$ Million)
Table 78. China Oligonucleotide Drugs (ONs) Sales by Application (2018-2024) & (K Units)
Table 79. China Oligonucleotide Drugs (ONs) Sales by Application (2024-2029) & (K Units)
Table 80. China Oligonucleotide Drugs (ONs) Revenue by Application (2018-2024) & (US$ Million)
Table 81. China Oligonucleotide Drugs (ONs) Revenue by Application (2024-2029) & (US$ Million)
Table 82. Asia Oligonucleotide Drugs (ONs) Sales by Type (2018-2024) & (K Units)
Table 83. Asia Oligonucleotide Drugs (ONs) Sales by Type (2024-2029) & (K Units)
Table 84. Asia Oligonucleotide Drugs (ONs) Revenue by Type (2018-2024) & (US$ Million)
Table 85. Asia Oligonucleotide Drugs (ONs) Revenue by Type (2024-2029) & (US$ Million)
Table 86. Asia Oligonucleotide Drugs (ONs) Sales by Application (2018-2024) & (K Units)
Table 87. Asia Oligonucleotide Drugs (ONs) Sales by Application (2024-2029) & (K Units)
Table 88. Asia Oligonucleotide Drugs (ONs) Revenue by Application (2018-2024) & (US$ Million)
Table 89. Asia Oligonucleotide Drugs (ONs) Revenue by Application (2024-2029) & (US$ Million)
Table 90. Asia Oligonucleotide Drugs (ONs) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 91. Asia Oligonucleotide Drugs (ONs) Revenue by Region (2018-2024) & (US$ Million)
Table 92. Asia Oligonucleotide Drugs (ONs) Revenue by Region (2024-2029) & (US$ Million)
Table 93. Asia Oligonucleotide Drugs (ONs) Sales by Region (2018-2024) & (K Units)
Table 94. Asia Oligonucleotide Drugs (ONs) Sales by Region (2024-2029) & (K Units)
Table 95. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales by Type (2018-2024) & (K Units)
Table 96. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales by Type (2024-2029) & (K Units)
Table 97. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue by Type (2018-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue by Type (2024-2029) & (US$ Million)
Table 99. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales by Application (2018-2024) & (K Units)
Table 100. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales by Application (2024-2029) & (K Units)
Table 101. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue by Application (2018-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue by Application (2024-2029) & (US$ Million)
Table 103. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 104. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue by Country (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue by Country (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales by Country (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales by Country (2024-2029) & (K Units)
Table 108. Novartis Company Information
Table 109. Novartis Description and Major Businesses
Table 110. Novartis Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. Novartis Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Novartis Recent Developments
Table 113. Ionis Company Information
Table 114. Ionis Description and Major Businesses
Table 115. Ionis Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. Ionis Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Ionis Recent Developments
Table 118. Nippon Shinyaku Company Information
Table 119. Nippon Shinyaku Description and Major Businesses
Table 120. Nippon Shinyaku Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Nippon Shinyaku Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Nippon Shinyaku Recent Developments
Table 123. Alnylam Company Information
Table 124. Alnylam Description and Major Businesses
Table 125. Alnylam Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. Alnylam Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Alnylam Recent Developments
Table 128. Sarepta Therapeutics Company Information
Table 129. Sarepta Therapeutics Description and Major Businesses
Table 130. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Sarepta Therapeutics Recent Developments
Table 133. MiNA Therapeutics Company Information
Table 134. MiNA Therapeutics Description and Major Businesses
Table 135. MiNA Therapeutics Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. MiNA Therapeutics Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. MiNA Therapeutics Recent Developments
Table 138. BioNTech Company Information
Table 139. BioNTech Description and Major Businesses
Table 140. BioNTech Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 141. BioNTech Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. BioNTech Recent Developments
Table 143. Moderna Company Information
Table 144. Moderna Description and Major Businesses
Table 145. Moderna Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 146. Moderna Oligonucleotide Drugs (ONs) Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Moderna Recent Developments
Table 148. Key Raw Materials Lists
Table 149. Raw Materials Key Suppliers Lists
Table 150. Oligonucleotide Drugs (ONs) Distributors List
Table 151. Oligonucleotide Drugs (ONs) Customers List
Table 152. Oligonucleotide Drugs (ONs) Market Trends
Table 153. Oligonucleotide Drugs (ONs) Market Drivers
Table 154. Oligonucleotide Drugs (ONs) Market Challenges
Table 155. Oligonucleotide Drugs (ONs) Market Restraints
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Oligonucleotide Drugs (ONs) Product Picture
Figure 2. Global Oligonucleotide Drugs (ONs) Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Oligonucleotide Drugs (ONs) Market Share by Type in 2022 & 2029
Figure 4. ASO Product Picture
Figure 5. siRNA Product Picture
Figure 6. Other Product Picture
Figure 7. Global Oligonucleotide Drugs (ONs) Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Oligonucleotide Drugs (ONs) Market Share by Application in 2022 & 2029
Figure 9. Cardiovascular Diseases
Figure 10. Hepatitis B
Figure 11. Hypertension
Figure 12. Other
Figure 13. Oligonucleotide Drugs (ONs) Report Years Considered
Figure 14. Global Oligonucleotide Drugs (ONs) Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Oligonucleotide Drugs (ONs) Revenue 2018-2029 (US$ Million)
Figure 16. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 17. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Region (2018-2029)
Figure 18. Global Oligonucleotide Drugs (ONs) Sales 2018-2029 ((K Units)
Figure 19. Global Oligonucleotide Drugs (ONs) Sales Market Share by Region (2018-2029)
Figure 20. US & Canada Oligonucleotide Drugs (ONs) Sales YoY (2018-2029) & (K Units)
Figure 21. US & Canada Oligonucleotide Drugs (ONs) Revenue YoY (2018-2029) & (US$ Million)
Figure 22. Europe Oligonucleotide Drugs (ONs) Sales YoY (2018-2029) & (K Units)
Figure 23. Europe Oligonucleotide Drugs (ONs) Revenue YoY (2018-2029) & (US$ Million)
Figure 24. China Oligonucleotide Drugs (ONs) Sales YoY (2018-2029) & (K Units)
Figure 25. China Oligonucleotide Drugs (ONs) Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Asia (excluding China) Oligonucleotide Drugs (ONs) Sales YoY (2018-2029) & (K Units)
Figure 27. Asia (excluding China) Oligonucleotide Drugs (ONs) Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales YoY (2018-2029) & (K Units)
Figure 29. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue YoY (2018-2029) & (US$ Million)
Figure 30. The Oligonucleotide Drugs (ONs) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Oligonucleotide Drugs (ONs) in the World: Market Share by Oligonucleotide Drugs (ONs) Revenue in 2022
Figure 32. Global Oligonucleotide Drugs (ONs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Oligonucleotide Drugs (ONs) Sales Market Share by Type (2018-2029)
Figure 34. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2018-2029)
Figure 35. Global Oligonucleotide Drugs (ONs) Sales Market Share by Application (2018-2029)
Figure 36. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Application (2018-2029)
Figure 37. US & Canada Oligonucleotide Drugs (ONs) Sales Market Share by Type (2018-2029)
Figure 38. US & Canada Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2018-2029)
Figure 39. US & Canada Oligonucleotide Drugs (ONs) Sales Market Share by Application (2018-2029)
Figure 40. US & Canada Oligonucleotide Drugs (ONs) Revenue Market Share by Application (2018-2029)
Figure 41. US & Canada Oligonucleotide Drugs (ONs) Revenue Share by Country (2018-2029)
Figure 42. US & Canada Oligonucleotide Drugs (ONs) Sales Share by Country (2018-2029)
Figure 43. U.S. Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 44. Canada Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 45. Europe Oligonucleotide Drugs (ONs) Sales Market Share by Type (2018-2029)
Figure 46. Europe Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2018-2029)
Figure 47. Europe Oligonucleotide Drugs (ONs) Sales Market Share by Application (2018-2029)
Figure 48. Europe Oligonucleotide Drugs (ONs) Revenue Market Share by Application (2018-2029)
Figure 49. Europe Oligonucleotide Drugs (ONs) Revenue Share by Country (2018-2029)
Figure 50. Europe Oligonucleotide Drugs (ONs) Sales Share by Country (2018-2029)
Figure 51. Germany Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 52. France Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 53. U.K. Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 54. Italy Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 55. Russia Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 56. China Oligonucleotide Drugs (ONs) Sales Market Share by Type (2018-2029)
Figure 57. China Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2018-2029)
Figure 58. China Oligonucleotide Drugs (ONs) Sales Market Share by Application (2018-2029)
Figure 59. China Oligonucleotide Drugs (ONs) Revenue Market Share by Application (2018-2029)
Figure 60. Asia Oligonucleotide Drugs (ONs) Sales Market Share by Type (2018-2029)
Figure 61. Asia Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2018-2029)
Figure 62. Asia Oligonucleotide Drugs (ONs) Sales Market Share by Application (2018-2029)
Figure 63. Asia Oligonucleotide Drugs (ONs) Revenue Market Share by Application (2018-2029)
Figure 64. Asia Oligonucleotide Drugs (ONs) Revenue Share by Region (2018-2029)
Figure 65. Asia Oligonucleotide Drugs (ONs) Sales Share by Region (2018-2029)
Figure 66. Japan Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 67. South Korea Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 68. China Taiwan Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 69. Southeast Asia Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 70. India Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 71. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Revenue Share by Country (2018-2029)
Figure 76. Middle East, Africa and Latin America Oligonucleotide Drugs (ONs) Sales Share by Country (2018-2029)
Figure 77. Brazil Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 78. Mexico Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 79. Turkey Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 80. Israel Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 81. GCC Countries Oligonucleotide Drugs (ONs) Revenue (2018-2029) & (US$ Million)
Figure 82. Oligonucleotide Drugs (ONs) Value Chain
Figure 83. Oligonucleotide Drugs (ONs) Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed